Get the Stockscreener App
0.5835
4.46%
0.0249
After Hours:
.59
0.0065
+1.11%
Century Therapeutics Inc stock is traded at $0.5835, with a volume of 1.25M.
It is up +4.46% in the last 24 hours and up +14.34% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.5586
Open:
$0.5801
24h Volume:
1.25M
Relative Volume:
1.68
Market Cap:
$50.41M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2548
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
+16.75%
1M Performance:
+14.34%
6M Performance:
+49.96%
1Y Performance:
-60.03%
1-Day Range:
$0.5701
$0.60
1-Week Range:
$0.484
$0.60
52-Week Range:
$0.3418
$1.83
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5835 | 48.26M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding - simplywall.st
How to escape a deep drawdown in Century Therapeutics Inc.July 2025 Update & Verified Momentum Stock Watchlist - newser.com
What the charts say about Century Therapeutics Inc. today2025 Price Momentum & Short-Term Trading Alerts - newser.com
Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $3.75 - Defense World
Century Therapeutics Inc. recovery potential after sell offMarket Activity Recap & Risk Controlled Stock Pick Alerts - newser.com
How to build a dashboard for Century Therapeutics Inc. stockJobs Report & Community Consensus Trade Signals - newser.com
Is Century Therapeutics Inc. stock positioned well for digital economyEarnings Trend Report & Expert Approved Momentum Ideas - newser.com
How Century Therapeutics Inc. stock trades before earningsWeekly Risk Summary & Daily Technical Forecast Reports - newser.com
Is Century Therapeutics Inc. stock ready for a breakoutMarket Risk Analysis & Fast Moving Trade Plans - newser.com
Why Century Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Century Therapeutics, Inc. $IPSC Position Boosted by Goldman Sachs Group Inc. - Defense World
Century Therapeutics (NASDAQ:IPSC) Shares Down 1.9% – What’s Next? - Defense World
What indicators show strength in Century Therapeutics Inc.2025 Market Trends & Scalable Portfolio Growth Methods - newser.com
What analysts say about Century Therapeutics Inc stockTechnical Resistance Breaks & Learn to Pick Stocks in Under 10 Minutes - Early Times
Flowco Holdings Inc Stock Analysis and ForecastMarket Sentiment Indicators & Small Entry Cost Trading - Early Times
Top chart patterns to watch in Century Therapeutics Inc.2025 Top Decliners & AI Forecasted Entry and Exit Points - newser.com
Contrasting Nutriband (NASDAQ:NTRB) & Century Therapeutics (NASDAQ:IPSC) - Defense World
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pfeiffenberger Brent | President and CEO |
Sep 08 '25 |
Sale |
0.50 |
488 |
244 |
3,268,909 |
| Russotti Gregory | See Remarks |
Sep 08 '25 |
Sale |
0.50 |
539 |
270 |
391,508 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):